• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Specialty Pharma

AQL:GR

0.912 EUR 0.018 2.01%

As of 05:04:19 ET on 10/21/2014.

Snapshot for ArQule Inc (AQL)

Open: 0.905 Day's Range: 0.903 - 0.912 Volume: 0
Previous Close: 0.894 52wk Range: 0.810 - 2.381 1-Yr Rtn: -47.13%

Stock Chart for AQL

No chart data available.
  • AQL:GR 0.903
  • 1D
  • 1M
  • 1Y
0.894
Interactive AQL Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for AQL

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -0.4850
Est. PEG Ratio -
Market Cap (M EUR) 57.25
Shares Outstanding (M) 62.77
30 Day Average Volume 460
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 11/07/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for AQL

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for AQL

ArQule Inc. develops cancer therapeutics based on its proprietary Activated Checkpoint Therapy platform. The Company's platform is designed to produce small molecule compounds that selectively kill cancer cells while leaving normal cells unharmed. ArQule's products are intended to be effective against multiple types of cancer.

Paolo PucciChief Executive OfficerPeter S LawrencePresident/COO/Secy/Gen Cnsl
Brian SchwartzSenior VP/Chief Medical OfcrWilliam B BoniVP:Investor Relations
More Company Profile & Key Executives for AQL

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil